Erectile dysfunction (ED) is a cause of decreased quality of life in more than 70% of diabetic men. Vascular endothelial growth factor (VEGF) has shown to improve overall endothelial and smooth muscle cell dysfunction in models of ED. We describe a novel technique for nonviral, in vivo gene transfection of VEGF in the rat corpus cavernosum. Diabetic rats were transfected with DNA encoding a fusion VEGF/green fluorescent protein (GFP) complex and fluorescence microscopy was used to monitor the expression of VEGF-GFP fusion protein. Western blot and PCR analyses confirmed the expression of the GFP-VEGF fusion protein and mRNA. Functional studies using cavernous nerve stimulation revealed maximal intracavernous pressures (ICPs) of 63.1 mm Hg, and 30.7 mm Hg in the normal and diabetic control groups, respectively, and 47.4 mm Hg in VEGF-GFPtransfected diabetic group. Immunohistochemical analysis of the cavernosal tissue from transfected rats showed increased smooth muscle content compared with the diabetic control group. We show for the first time in our animal model that expression of the transfected VEGF in cavernosal tissue leads to an overall improvement of maximal ICP and smooth muscle content. On the basis of these results, it is tempting to speculate that our nonviral vector system offers an excellent system for gene delivery into cavernosal tissue, and that VEGF gene therapy using this system could be useful in improving erectile function in diabetic men.
Introduction
Erectile dysfunction (ED) is a common cause of decreased quality of life in men and has multiple etiologies and risk factors. The incidence of ED in diabetic men is greater than 70%, and many men in this population do not respond to the currently available treatment options, including oral phosphodiesterase-5 inhibitors. The etiology of ED in diabetic men is believed to be both neuropathic as well as vasculogenic. However, recent evidence demonstrates a significant component of endothelial cell dysfunction, likely contributing to the ineffectiveness of phosphodiesterase-5 inhibitors whose target is within the endothelial cell. A study by Lue et al. showed a decrease in endothelial cell size and number in castrated rats with venous insufficiency. 1 Gene therapy continues to rise to the forefront of novel techniques to treat ED. The potential for gene therapy technology to treat ED is facilitated by the anatomically easy accessibility for injection treatment. Furthermore, the anatomy of the penis allows for occlusion of the base as medications are injected into the paired cavernosa. However, for such treatments to be practical, they must have a high safety profile and their effectiveness must compete with current highly effective 'on demand' oral and injection therapies. Several genes have been targeted for possible therapies, including hSlo calcium-sensitive K þ channel, endothelial nitric oxide synthase, (neuronal nitric oxide synthase , vascular endothelial growth factor (VEGF), vasoactive intestinal peptide and brain-derived neurotrophic factor. [2] [3] [4] [5] [6] [7] [8] Many techniques of gene delivery systems exist, each with their respective advantages and disadvantages. Viral delivery systems remain the most widely used in research today. Their advantages include easy construction and high transfection efficiency. However, several disadvantages exist including serious allergic reactions to viral vectors and the fact that the DNA is incorporated into the host's chromosome. For these reasons, viral vectors are not often used in human trials for treatments of non-fatal diseases such as ED. This has led others to pursue alternate gene delivery systems including naked DNA and nonviral carriers.
Several nonviral gene transfection reagents are commercially available. Polyethylenimine (PEI) is an organic macromolecule that offers the highest cationic charge density potential due to the abundant nitrogen amine groups capable of protonation. 9 It exists in either branched or linear forms and has undergone many modifications by various investigators to increase solubility, half-life, cellular uptake and nuclear delivery while decreasing cytotoxicity. 10, 11 The optimal formulation for a given application appears to be dependent on the specific target tissue.
VEGF is a potent endothelial cell mitogen that has been shown to improve erectile function in several animal models of ED, including hypercholesterolemic rabbit 7, 12 and diabetic rat models. 13, 14 In several studies, injection of VEGF protein has been shown to protect endothelial cell and smooth muscle cell apoptosis by the upregulation of the anti-apoptotic protein Bcl-2. 15, 16 Further, gene therapy using an adenovirus-associated transfection reagent prevented the venous insufficiency associated with castrated rats with a concomitant endothelial cell hypertrophy and hyperplasia. 1 We have recently described the novel use of a linear, PEI gene delivery system (Polyplus Transfection SA, Illkrich, France) to transfect cells of the rat corpus cavernosum with continued protein expression up to 4 weeks after a single injection. The objective of the current study is to reverse the ED in a rat model of diabetes with an injection of DNAencoding VEGF using a nonviral gene delivery system.
Materials and methods

Experimental animals
A total of 20 Sprague-Dawley rats, 6 months old and weighing between 300 and 325 g were used in this study. The rats were divided into three groups: normal control, diabetic control and diabetic treated with VEGF gene therapy. The 10 rats in the diabetic group received a single, intraperitoneal injection of streptozotocin (40 mg kg
À1
) dissolved in a citrate phosphate buffer (0.1 M citric acid and 0.2 M disodium phosphate, pH 7.0) to induce diabetes. Weekly blood sugar and body weight measurements were followed, and animals were considered diabetic when the blood sugar was greater than 250 g per 100 ml. All animals were housed in our animal facility and given a continuous supply of food and water. All treatments and procedures were approved by the animal research committee at our institution.
Construction of green fluorescent protein (GFP)/VEGF plasmid Vascular endothelial growth factor was cloned from LNCaP cell cDNA library using forward and reverse primers sets 5 0 GATGCTAGCCACCATGAACTTTCT GCTGTCTTGGGTGC-3 0 and 5 0 -CGATACCGGTACC TTGTCATCGTCGTCCTTGTAGTCCCGCCTCGGCTT GTCACATCTGC-3 0 , respectively, complementary to 1039 and 1686 nucleotides in VEGF reference sequence NM_003376. In addition, the forward primer has an Nhe1 restriction enzyme digestion site and the reverse primer has Age1 restriction enzyme digestion site. VEGF cDNA was amplified and PCR products were separated on a 1% agarose gel and purified on a DNA purification column (Qiagen, Valencia, CA, USA). The VEGF cDNA was sequenced at the University of Colorado Genomics Core laboratory to confirm the sequence. This sequence information has been reported previously. 17 The purified VEGF insert was digested with Nhe1 and Age1 restriction enzymes, and directionally cloned into pEGFP-C1 vector (Clontech Laboratories Inc., Mountain View, CA, USA) at Nhe1(592) and Age1 (601) sites. The VEGF-GFP insert (approximately 1.42 kb) was excised from the vector using Nhe1 and Sal1 and directionally cloned into pDC315 (Microbix, Division of Alliance H. Inc) at Nhe1 (1005) and Sal1 (1024). The expression VEGF-GFP-fusion protein was confirmed by transfection into human embryonic kidney cells (HEK-293 cells). We used pDC315 empty vector as control or pDC315-VEGF-GFP as expression vector for the present study. This system allows for expression of cloned proteins to be expressed under cytomegalovirus promoter as well. In this study, we primarily used pEGFP vector to generate VEGF-GFP fusion gene.
Preparation of PEI/plasmid complexes
The PEI/plasmid complexes were created following the manufacturer's protocol to obtain a PEI nitrogen to DNA phosphate ratio (N:P) of 10. For each injection, 10 mg of GFP/VEGF plasmid DNA was diluted into a 5% glucose solution for a total volume of 50 ml. This was vortexed briefly and spun down. Ten microliters of in vivo jetPEI solution was mixed with 40 ml of a 5% glucose solution and briefly vortexed and spun down. The solution containing VEGF gene therapy improves erectile function in a diabetic rat model JE Dall'Era et al the PEI was then added to the solution containing the GFP plasmid DNA and this was vortexed lightly and briefly spun down. The reaction was allowed to incubate at room temperature for 15 min before animal injection.
Injection protocol
Animals were given isoflurane-inhaled anesthesia and a 1.5 cm midline skin incision was made overlying the penis. The penis was dissected free of the surrounding tissue and retracted anteriorly until the base and the crura were exposed. Further dissection of the surrounding tissue was performed until the white tunica albuginea overlying the corpora was visible. A constriction band was then placed at the base of the penis. Each animal was subsequently injected with a total volume of 100 ml into the corpora using a 26-gauge needle distal to the constriction band. Following each injection, the needle was left in place with the constriction band applied for 5 min. The constriction band was then removed and hemostasis was achieved with pressure if necessary. The overlying skin was then closed with a 5-0 absorbable suture, and the animal was allowed to wake up on a heating pad. All procedures were performed using an aseptic technique and euthanasia was carried out with an intra-cardiac injection of sodium pentobarbital (Sleepaway, Fort Dodge Animal Health, Fort Dodge, IA, USA).
Functional studies
Functional studies were performed in rats 9 weeks after the injection of streptozotocin and 3 weeks after the intercavernosal injection of PEI/plasmid complexes. Each rat was anesthetized with sodium pentobarbital (40 mg kg À1 , Nembutal) and a low, midline incision was made. The lateral prostatic spaces were explored and the cavernous nerves identified as they branched from the major pelvic ganglia. Two stainless steel electrodes were placed around the cavernous nerve on one side; with the negative electrode approximately 1 mm distal to the positive electrode. The skin overlying the penis was then opened and the crura were dissected free of overlying tissue. A 26-gauge needle filled with heparin (250 U ml À1 ) was inserted into either the right or left crus and connected to a pressure monitor with polyethylene tubing filled with the heparin solution. Electrostimulation was performed using a stimulator (World Precision Instruments, Sarasota, FL, USA) at the following settings: 1.5 mA constant current, 20 Hz frequency, 0.2 ms pulse width, and 60 s duration. Increases in intracavernous pressure were measured and recorded using the Data-Trax data acquisition software (Destributed Design Concepts, Dover, NH, USA).
Tissue procurement
Following the functional analysis, the penis was amputated at the base and immediately cut in half along the transverse axis. One half of the tissue was placed in ice-cold protein lysis buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1% Triton, 0.5% NP-40, 10% glycerol, 2 mM EDTA, 2 mM EGTA, 1 mM sodium vanadate) and stored at À801 C. The other half was stored in an RNA stabilization reagent (Qiagen) and stored at 41 C for reverse transcriptase-PCR studies. Tissue from 2 rats in each group was placed in buffered formalin for 24 h and then stored in 70% ethanol for immunohistochemical analysis. Fluorescence microscopy for the detection of GFP was performed on each sample before mechanical disruption.
Western blot analysis of GFP Penile tissue was mechanically disrupted while in the protein lysis buffer using mechanical homogenization and 10 s of sonication. A unit of 100 mg of protein was loaded onto a 10% SDS-polyacrylamide gel electrophoresis gel and run at 120 V for 90 min. The protein was then transferred to a PVDF membrane and subsequently blocked for 2 h with 10% milk in TBST (10 mM Tris base pH 7.5, 150 mM NaCl, 0.1% Tween-20). The membrane was then incubated in primary polyclonal antibody against GFP (cell signaling, no. 3555) or VEGF (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA, SC-152) for 90 min. After three washes with TBST for 10 min each, the membrane was placed in the secondary goat-anti-rabbit antibody (Rockland Immunochemicals Inc., Gilbertsville, PA, USA) for 1 hour. The enhanced chemiluminescence reaction (ECL, Amersham Biosciences, Piscataway, NJ, USA) was then carried out according to the manufacturer's instructions and films were developed for 30 s.
RNA extraction
Penile tissue was harvested and immediately placed in an RNA stabilization buffer (Qiagen). The tissue was mechanically disrupted using a tissue homogenizer and the RNA was isolated according to the manufacturer's instructions (Qiagen, RNeasy mini kit). The final precipitation was performed with 30 ml of RNAse/DNAse-free sterile water. RNA quantification was then performed with spectrophotometry by determining the A260 and A280.
DNAse treatment and formation of cDNA To remove any residual plasmid DNA in the purified RNA, 1 mg of RNA was added to a 10 ml reaction containing 1.5. mM EDTA, 2 U DNAse (Novagen, EMD Biosciences, San Diego, CA, USA), and RT buffer (Bio-Rad Laboratories, Hercules, CA, USA),
and incubated at 371 C for 30 min. A subsequent incubation at 701 C for 10 min was used to deactivate the DNAse enzyme. Reverse transcriptase enzyme was then added with the appropriate buffer for a 20 ml reaction to create cDNA according to manufacturer's instructions (Bio-Rad, iSCRIPT cDNA synthesis kit). The reaction was performed at 251 C for 5 min, 421 C for 30 min, 851 C for 5 min, and held at 41 C.
PCR
Three microliters of the reverse transcriptase reaction cDNA product was amplified in a 25 ml reaction containing 0.5 U Taq DNA polymerase, 0.2 mM deoxynucleoside triphosphate mixture, 0.2 mM sense and antisense primers (VEGF/GFP), 1.5 mM magnesium chloride, and 1 X PCR buffer (Invitrogen Corporation, Carlsbad, CA, USA). The reaction was performed in a Bio-Rad thermal cycler using the following parameters: cycle 1, denaturation at 941 C for 4 min; cycle 2 (30 repetitions), 941 C for 45 s, 581 C for 1 min, and 721 C for 1 min; cycle 3, 721 C for 10 min; and cycle 4, held at 41 C. Ten microliters of the PCR product were electrophoresed on a 1% agarose gel stained with 0.5 mg ml À1 ethidium bromide alongside a 1 kbp ladder (Invitrogen). The gel was then viewed with an ultraviolet light box. Table 1 lists the sense and antisense primer sequences for GFP and VEGF.
Immunohistochemistry Five-micrometer sections were deparafinized in xylene and rehydrated through sequential steps of 100, 95 and 75% ethanol. Antigen unmasking was performed by immersing the slides in a citrate buffer (10 mM sodium citrate, 0.05% Tween-20, pH 6.0) and placing in a microwave on high for a total of 15 min. Endogenous peroxidase was then quenched by immersing the tissue in 3% hydrogen peroxide for 5 min. The tissue was then blocked in goat serum for 30 min. Primary antibody against the VEGF receptor (Santa Cruz, SC-316) was then added at a 1:100 dilution in blocking buffer and allowed to incubate for 90 min. The slides were then washed with phosphate-buffered saline and incubated for 45 min with a biotin-conjugated secondary antibody (Vector labs, Burlingame, CA, USA). After an additional wash with phosphate-buffered saline , the slides were incubated with avidin-biotin complexes for 50 min. A peroxidase reagent was applied for 20 min, followed by incubation with AEC chromogen solution (Sigma) for 10 min. The reaction was stopped by immersing the slides in tap water. Counterstaining was performed using Mayer's hematoxylin (Sigma) for 2 min. Trichrome staining was performed by the Department of Histology at the University of Colorado.
Statistical analysis
All statistical analyses were performed with a paired t-test using Microsoft Excel. Figure 1 shows images of intact penile tissue transfected with plasmid DNA encoding the GFP/ VEGF fusion protein under fluorescence microscopy.
Results
GFP microscopy
Table 1 Primers for PCR analysis
Gene
Forward primer Reverse primer
Normal Transfected Figure 1 Visualization of GFP expression 3 weeks after an injection with DNA encoding a GFPA/EGF fusion protein. Penile tissue taken from rats receiving an injection of (a) plasmid DNA not encoding the GFPA/EGF fusion protein and (b) DNA encoding the GFPA/EGF fusion protein under ultraviolet microscopy. EGF, endothelial growth factor; GFP, green fluorescent protein.
VEGF gene therapy improves erectile function in a diabetic rat model JE Dall'Era et al
Control rats received an injection containing the plasmid only. After 3 weeks from the time of a single injection, GFP expression continues to be detected. The penile tissue from rats receiving only the plasmid injection did not display any green fluorescence.
Effect of diabetes and VEGF gene therapy on functional studies
The mean maximal intracavernous pressure in the diabetic group (31 mm Hg) was significantly lower than the normal controls (63 mm Hg) and the diabetic group receiving the VEGF gene therapy (47 mm Hg) (Figure 2 ). Figure 3 shows representative recordings of the intracavernous pressures measured in each of the study groups. Treatment with the VEGF gene therapy resulted in significantly increased readings 3 weeks after a single transfection compared to the diabetic control group. Figure 4 shows a western blot of GFP/VEGF fusion protein expression in tissue harvested from rats transfected with 10 mg of the plasmid with and without the gene for GFP/VEGF. There is clear expression of the fusion protein in the experimental animals when stained using anti-GFP antibody. Equal gel loading was confirmed with glyceraldehyde-3-phosphate dehydrogenase expression and the location of the GFP/VEGF fusion band was confirmed using anti-VEGF antibody.
GFP/VEGF fusion protein expression
GFP/VEGF mRNA expression Figure 5 shows mRNA expression of the GFP/VEGF fusion protein using the forward GFP primer and reverse VEGF primer. The product is found in the 
Control
Diabetic VEGF 100 50 0 mm Hg Figure 3 Representative ICP curves after cavernous nerve electrostimulation. The VEGF treated rats had a significantly higher response to stimulation than the diabetic group.ICP, intracavernous pressure; VEGF, vascular endothelial growth factor.
GFP / VEGF
GAPDH Positive transfected transfected transfected negative Figure 4 Western blot analysis of eGFP/VEGF fusion protein expression using antibody against GFP (MW of fusion protein ¼ 50 kDa). Protein expression is evident in tissue taken from rats receiving a transfection of 10 mg eGFP/VEGF DNA. The negative and positive controls are taken from rats receiving an injection of plasmid carrier only and tissue culture cells (293T) transfected with the eGFP/VEGF construct, respectively. GAPDH staining is performed for gel loading control. EGF, endothelial growth factor; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GFP, green fluorescent protein.
plasmid control transfected Figure 5 RT-PCR using primers specific for eGFP/VEGF fusion protein. Rat penile tissue was harvested 3 weeks after a single injection of 10 mg plasmid DNA encoding GFP. The negative control consists of tissue taken from a rat injected with plasmid carrier only, and the positive control is plasmid DNA encoding the eGFP/VEGF fusion protein created in our laboratory. EGF, endothelial growth factor; GFP, green fluorescent protein; RT-PCR, reverse transcriptase-PCR.
VEGF gene therapy improves erectile function in a diabetic rat model JE Dall'Era et al transfected tissue 3 weeks after a single injection. Tissue from the control group did not express the GFP/VEGF mRNA. Figure 6 shows representative stains of penile tissue taken from each group using the Masson's trichrome stain and anti-VEGF receptor immunostaining. The trichrome stain reveals decreased smooth muscle and increased collagen in tissue taken from diabetic rats. In rats treated with a single transfection of DNA encoding GFP/VEGF, the smooth muscle content is restored to almost a normal appearance. In addition, immunostaining for the VEGF receptor reveals increased expression in the transfected tissue.
Histological analysis
Discussion
Despite the advances made in medical therapies for ED, a significant portion of diabetic men do not respond and ultimately end up with a surgically placed penile prosthesis. Recently, many investigators have turned to novel gene therapies in the development of new treatments for ED. However, gene therapy options for the treatment of such nonfatal diseases rightly receive much scrutiny for their efficacy and safety. Many of the currently utilized modalities for gene delivery do not pass the safety profile for treatment of nonfatal diseases. Viral vectors, for example, can incite a significant immune reaction and prove unsafe for the host. For this reason, many investigators have focused on the use of nonviral carriers or naked DNA to carry therapeutic genes to the target organs due to their low side-effect profile. We have previously reported success with a preparation of water-soluble, linear polyethyleneimine to transfect the rat corpus cavernosum, and have used this technique for gene therapy studies in a rat model of diabetic ED. 18 Although our results suggest that Jet PEI is a safe and effective agent for in vivo gene delivery, the safety profile of this agent has not been completely evaluated in the present study. Moreover, formal survival studies have not been attempted in the current study, but will be done in the future before any advancement to human trials.
The etiology of ED secondary to diabetes is multifactorial, with components of neurologic and vascular insufficiency. Further, it has been clearly demonstrated that a common histological endpoint of decreased smooth muscle and increased collagen deposition exists in animal models of diabetic ED leading to venous insufficiency. 19 With this information, many proteins have been targeted by several investigators as potential treatments for this disease including VEGF, endothelial nitric oxide synthase and inducible nitric oxide synthase. However, based on several recently published series, VEGF appears to have the most impressive results. Yamanaka et al. 13 and Shirai et al.
14 showed a restoration of smooth muscle architecture and improved ICP measurements in diabetic rats after treatment with VEGF protein injections. The goal of the present study was to evaluate the effects of VEGF gene therapy on a similar diabetic rat model of ED using our technique for gene delivery to the cavernosum.
To validate our rat model of ED secondary to diabetes, histological analysis of penile tissue and functional cavernosometry were performed 6 weeks VEGF gene therapy improves erectile function in a diabetic rat model JE Dall'Era et al after confirmation of severe hyperglycemia. Rats in which diabetes was confirmed showed a significantly reduced erectile response to cavernous nerve stimulation. Similarly, these rats showed a histological decrease in smooth muscle content and increase in collagen within the cavernosal tissue. These results are in agreement with previously published studies on a rat model of ED secondary to diabetes. This model was then used to evaluate the efficacy of treating diabetic ED with gene therapy for VEGF. We chose to study the effects 3 weeks after a single injection of DNA encoding VEGF, as this was the duration to maximal gene expression in our previous studies. Confirmation of protein expression was performed using fluorescence microscopy to detect the expression of GFP and western blot analysis for both GFP and VEGF expression. Additionally, mRNA expression was demonstrated using reverse transcriptase-PCR with primers specific for the GFP/VEGF fusion protein. Histological analysis of penile tissue taken from treated rats resembled normal rats when compared with smooth muscle and collagen content. This was a dramatic improvement when compared to tissue from diabetic rats not treated with VEGF gene therapy. Finally, the maximal intracavernous pressure achieved in rats treated with VEGF gene therapy was significantly increased over the diabetic control rats.
Conclusions
The technique presented here for the transfection of the rat corpus cavernosum is a safe, efficient technique for the application of gene therapy for the treatment of ED. This study and our other work, which demonstrate this method, allows for continuous gene expression for 3 weeks after a single injection of 10 mg DNA. This represents a much longer duration of gene expression for a significantly smaller quantity of DNA injected when compared with most published animal studies.
The expression of VEGF in a diabetic rat model of ED leads to improvement in the histological composition of the cavernosal tissue as well as functional erectile status. A single injection of a small quantity of DNA was sufficient to see these improvements 3 weeks after the treatment. These early studies using this gene delivery system, leading to increased expression of VEGF, may be instrumental in the success of future human trials of gene therapy to treat ED.
